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OBJECTIVE—Posttransplantation diabetes mellitus (PTDM) is
a major metabolic complication in renal transplant recipients,
and insulin secretory defects play an important role in the
pathogenesis of PTDM. The R325W (rs13266634) nonsynony-
mous polymorphism in the islet-specific zinc transporter protein
gene, SLC30A8, has been reported to be associated with type 2
diabetes and possibly with a defect in insulin secretion. This
study investigated the association between genetic variations in
the SLC30A8 gene and PTDM in renal allograft recipients.
RESEARCH DESIGN AND METHODS—A total of 624 unre-
lated renal allograft recipients without previously diagnosed
diabetes were enrolled. Rs13266634 was genotyped in the cohort,
which consisted of 174 posttransplantation diabetic patients and
450 non-posttransplantation diabetic subjects. The genotyping of
the SLC30A8 polymorphism was performed using real-time PCR.
RESULTS—The prevalence of PTDM was 33.8% in patients
carrying the R/R genotype, 26.8% in patients with the R/W
genotype, and 19.8% in patients with the W/W genotype. There
was a strong association between the number of W-alleles and
PTDM risk reduction (P for trend  0.007). Patients with at least
one T-allele showed a decreased risk of PTDM compared with
those with the R/R genotype (R/W, risk ratio [RR] 0.78, P 0.126;
W/W, RR 0.52, P  0.007). The effect of the SLC30A8 genotype
remained significant after adjustments for age, sex, body weight
gain, and type of immunosuppressant (R/W, hazard ratio [HR]
0.77, P  0.114; W/W, HR 0.58, P  0.026).
CONCLUSIONS—These data provide evidence that the SLC30A8
rs13266634 gene variation is associated with protection from the
development of PTDM in renal allograft recipients.Diabetes 57:
1043–1047, 2008
Posttransplantation diabetes mellitus (PTDM) is aserious metabolic complication and is associatedwith cardiovascular morbidity and mortality (1–3). Patients with PTDM have an increased risk for
long-term cardiovascular events of up to 3.27 times com-
pared with those without PTDM (4). The incidence of
PTDM ranges from 2 to 53% (5). A number of risk factors
for PTDM have been reported, including older age, ethnic-
ity, obesity, family history of diabetes, cadaver donor,
frequent acute rejection, hepatitis C infection, corticoste-
roid dose, and type of immunosuppressant therapy (2,6–
12). However, there are few studies on genetic risk factors
for the development of PTDM (13,14).
Although many studies have reported that insulin resis-
tance is important to the pathophysiology of PTDM, a
defect in insulin secretion may also play a role in the
development of PTDM (10,15). Insulin is stored in pancre-
atic -cells as zinc-insulin crystals. Zinc is believed to be
an important component of the insulin secretion mecha-
nism and may modulate insulin secretion (16–18). Zinc
transporter (Znt)-8 , expressed only in pancreatic -cells,
is thought to be the -cell zinc regulator (19–21). Recently,
a polymorphism in the ZnT-8 gene (SLC30A8) has been
associated with type 2 diabetes (22–25). This single nucle-
otide polymorphism (SNP), rs13266634, is a nonsynony-
mous SNP causing an amino acid change from arginine (R)
to tryptophan (W) at position 325. We investigated the
association between the SLC30A8 polymorphism and the
incidence of PTDM in renal allograft recipients.
RESEARCH DESIGN AND METHODS
A total of 805 unrelated transplant recipients were recruited from 1989 to
2007. PTDM was diagnosed according to American Diabetes Association
criteria (26) at the 3rd month posttransplantation. Patients who were started
on antidiabetic medication (oral medication or insulin) after transplantation
and continued the medication thereafter were included in the posttransplan-
tation diabetic group. The rest of the patients were assigned to the non-
posttransplantation diabetic group. According to our previous study (15),
cases of persistent PTDM (patients who developed diabetes within 1 year
posttransplantation and remained diabetic) and late PTDM (patients who
developed diabetes after 1 year posttransplantation) were assigned to the
posttransplantation diabetic group. Transient PTDM cases (patients who
developed diabetes within 1 year posttransplantation but eventually recovered
to normoglycemia without medication) were classified as non-PTDM.
Patients were eligible to participate in the study if they were the recipients
of a kidney allograft with no previous history of organ transplantation. Those
with no previous diagnosis of diabetes and a recorded fasting plasma glucose
(FPG) level 5.5 mmol/l were included. Patients were excluded if they had a
history of diabetes before transplantation, severe metabolic or infectious
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disease, or a recorded FPG level 5.5 mmol/l. A total of 624 unrelated renal
allograft recipients were enrolled in this study. Medical histories were
obtained during the initial visit, and family history of diabetes refers to
first-degree relatives only. Height and weight measurements were taken at the
time of transplantation and at 3 and 6 months after transplantation. Blood
samples were collected after an overnight fast. Frequency of patient follow-up
and data collected at follow-up visits are shown in the online appendix
(available at http://dx.doi.org/10.2337/db07-0761). Initial FPG level was mea-
sured on the day of transplantation using an enzymatic colorimetric assay.
Insulin concentration was measured using a radioimmunoassay kit (Dainabot,
Tokyo, Japan). Markers of insulin sensitivity and -cell insulin secretory
function were determined by the homeostasis model assessment (HOMA) of
insulin resistance (HOMA-IR) and -cell function (HOMA-) (27). HOMA-IR
was calculated as (fasting plasma insulin [U/ml]  FPG [mmol/l])/22.5 and
HOMA- as (20  fasting plasma insulin [U/ml])/(FPG [mmol/l]  3.5). The
study protocol was approved by the ethics committee of the Yonsei University
College of Medicine. All subjects were provided with adequate information
about this study and gave informed consent.
Immunosuppression. The immunosuppressive regimens consisted of cal-
cineurin inhibitors and glucocorticoids. Immunosuppressive regimens and
schedules were as reported previously (15) (online appendix).
DNA extraction and SLC30A8 genotyping. Genomic DNA was isolated
from peripheral blood lymphocytes. The genotyping of the SLC30A8 polymor-
phism rs13266634 was done using the TaqMan fluorogenic 5 nuclease assay
(ABI, Foster City, CA). The final reaction volume for the PCR was 5 l,
containing 10 ng genomic DNA, 2.5 l TaqMan Universal PCR Master Mix, and
0.13 l 40 Assay Mix (assay ID C2684958_10). Thermal cycling conditions
were as follows: 50°C for 2 min to activate the uracil N-glycosylase and
prevent carry-over contamination, 95°C for 10 min to activate the DNA
polymerase, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. All
PCRs were performed using 384-well plates by a Dual 384-Well GeneAmp PCR
System 9700 (ABI), and the endpoint fluorescent readings were performed on
an ABI PRISM 7900 HT Sequence Detection System. Forty-eight duplicate
samples and negative controls were included to ensure the accuracy of
genotyping, and 100% of the duplicates replicated the original genotype. The
genotype success rate was 99.48% for rs13266634.
Statistical analyses. The genotype frequencies were tested for Hardy-
Weinberg equilibrium using 2 test. All continuous variables were expressed
as means 	 SD. Student’s t test was used to compare continuous variables
between the PTDM and non-PTDM posttransplantation diabetic groups.
Pearson’s 2 test was used to evaluate the difference in the incidence of
diabetes between genotypes. ANOVA was used to compare continuous
variables among genotypes. Mantel-Haenzel 2 test (P for trend) was used to
evaluate the trend of diabetes protection with an increase in number of
W-alleles. Cox proportional hazards modeling was used to identify risk factors
for PTDM development and calculate the adjusted hazard ratio [HR] and 95%
CIs. Diabetes-free survival was calculated from the date of transplantation to
the date of PTDM diagnosis or last follow-up. Survival was estimated by
Kaplan-Meier method and compared using the log-rank test. Patient baseline
characteristics were assessed on transplant day. A P value 0.05 was
considered statistically significant. Statistical analyses were performed using
SPSS for Windows software (version 12.0; SPSS, Chicago, IL). Power calcu-
lations were performed using PASS software version 2005 (NCSS Statistical
Software, Kaysville, UT).
RESULTS
Clinical characteristics of posttransplantation dia-
betic patients. The overall incidence of PTDM in this
study population was 27.9%. Baseline clinical characteris-
tics of the recipients are shown in Table 1. The mean age
of patients at transplantation was 38.7 	 9.5 years. Pa-
tients in the posttransplantation diabetic group were older
than those in the non-posttransplantation diabetic group
(42.10 	 8.99 vs. 37.42 	 9.43 years old, P  0.001).
Posttransplantation diabetic patients were followed up for
a significantly longer period than non-posttransplantation
diabetic patients. Baseline mean body weight was 58.83 	
9.71 kg, and although initial body weight was not signifi-
cantly different between the two groups, there was a
significant difference in the amount of weight gain during
the first 6 months after transplantation between the two
groups (Table 1). The duration of dialysis, incidence of
acute rejection, and serum creatinine levels were not
different between the groups (Table 1). Patients who used
tacrolimus as an immunosuppressive agent had a higher
incidence of PTDM (P  0.031). There was no significant
difference in steroid dose between the groups (online
appendix).
Genotype distribution. The overall R-allele frequency
was 0.577 and the overall W-allele frequency was 0.423.
Overall genotype distributions were R/R, 33.17%; R/W,
49.04%; and W/W, 17.79%. Genotype distributions were in
agreement with Hardy-Weinberg equilibrium (2  0.013,
P  0.910) (Table 2).
Association between the SLC30A8 rs13266634 geno-
type and PTDM. PTDM developed in 174 patients (27.2%).
The W/W genotype conferred a reduced risk for PTDM
TABLE 1
Clinical characteristics of the study population
PTDM Non-PTDM P
n (% women) 174 (35.1) 450 (35.6) 0.907*
Age at transplantation (years) 42.10	 8.99 35.42	 9.43 0.001
Family history of diabetes (%) 100 (57.5) 256 (56.9) 0.895*
Follow-up duration (months) 113.02	 58.53 100.36	 62.26 0.018
BW at transplantation (kg) 59.01	 9.69 58.76	 9.72 0.771
BW at 3 months after transplantation (kg) 59.58	 9.32 58.54	 8.74 0.205
BW at 6 months after transplantation (kg) 62.68	 8.83 60.87	 8.99 0.023

BW during first 3 months after transplantation (kg) 0.57	 4.83 0.21	 4.29 0.061

BW during first 6 months after transplantation (kg) 3.66	 5.76 2.12	 5.22 0.002
FPG at transplantation (mmol/l) 5.31	 1.35 5.16	 1.44 0.254
FPG at 3 months after transplantation (mmol/l) 6.90	 3.61† 5.34	 0.78 0.001
FPG at 6 months after transplantation (mmol/l) 6.81	 3.18† 5.32	 0.73 0.001
FPG at 12 months after transplantation (mmol/l) 6.93	 2.85† 5.41	 0.85 0.001
Duration of dialysis (months) 17.48	 23.96 19.47	 29.98 0.449
No. of patients with acute rejection (%) 51 (29.3) 111 (24.7) 0.235*
No. of patients with tacrolimus use (%) 47 (27.0) 86 (19.1) 0.031*
Cr at 3 months after transplantation (mg/dl) 1.34	 0.43 1.36	 0.39 0.590
Cr at 6 months after transplantation (mg/dl) 1.31	 0.42 1.32	 0.34 0.749
Cr at 12 months after transplantation (mg/dl) 1.28	 0.42 1.33	 0.45 0.204
Data are means 	 SD or n (%) unless otherwise indicated. BW, body weight; 
BW, change in body weight. P values were calculated from
t test. *P values were calculated from the 2 test. †Included patients with antidiabetic medications.
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compared with the R/R genotype (risk ratio [RR] 0.52 [95%
CI 0.32–0.83], P  0.007; Table 2). The risk of PTDM was
marginally lower in carriers of the R/W genotype than in
R/R carriers (0.78 [0.57–1.07], P  0.126, Table 2). The
W-allele was associated with a decreased incidence of
PTDM in codominant (R/R, 33.8%; R/W 26.8%; W/W, 19.8%;
P  0.025), dominant (R/R, 33.8%; R/W plus W/W, 24.9%;
P  0.024), and recessive (R/R plus R/W, 29.6%; W/W,
19.8%; P  0.038) models (Table 2).
There was no difference among genotypes in age at
transplantation, initial body weight, amount of body
weight gain, FPG level (at baseline and at 3, 6, and 12
months after transplantation), duration of dialysis, per-
centage of tacrolimus use as an immunosuppressant,
incidence of acute rejection, or serum creatinine levels
(Table 3).
There was a linear increase in the HOMA- value from
the R/R genotype to the W/W genotype. Insulin secretory
function, assessed by HOMA-, was better preserved in
patients with the W/W genotype than in those with the R/R
genotype (Table 3). In contrast, no significant difference in
HOMA-IR value according to genotype was observed (Ta-
ble 3).
Independent risk factors of PTDM were identified using
multiple Cox proportional hazard regression. We included
age, sex, amount of body weight gain, type of immunosup-
pressant, and genotype as covariates in the multiple Cox
proportional hazard regression model because they were
associated with PTDM in univariate association tests
(Table 1). As shown in Table 4, the SLC30A8 genotype was
a significant independent risk factor of PTDM together
with age at transplantation and tacrolimus use as an
immunosuppressant. The effect of the genotype remained
significant after adjustments for age, sex, amount of
weight gain, and type of immunosuppressant used (R/W,
HR 0.77, P 0.114; W/W, HR 0.58, P 0.026). Age, amount
of weight gain, and tacrolimus use were associated with
PTDM development, but sex was not (Table 4).
The Kaplan-Meier curve for the development of PTDM is
shown in Fig. 1. Patients with the W/W genotype had a
significantly lower risk (P  0.007) of developing PTDM
than those with the R/R genotype.
TABLE 2
Genotype distribution and corresponding RR for PTDM
Genotype
Genotype effect
Codominant model Recessive model Dominant model
PTDM Non-PTDM RR (95% CI) P RR (95% CI) P RR (95% CI) P
R/R 70 (40.2)* 137 (30.4) 1
R/W 82 (47.1)* 224 (49.8) 0.78 (0.57–1.07) 0.126
W/W 22 (12.6)* 89 (19.8) 0.52 (0.32–0.84) 0.007 0.60 (0.38–0.94) 0.038 0.70 (0.52–0.96) 0.024
Data are n (%) unless otherwise indicated. The codominant model represents comparisons between R/R versus R/W genotypes and R/R
versus W/W genotypes. The recessive model represents the comparison between the R/R plus R/W versus W/W genotypes. The dominant
model represents the comparison of the R/R versus R/W plus W/W genotypes. *P  0.025 when comparing three groups using 2 test and P 
0.007 when calculated from the Mantel-Haenzel 2 test (P trend test).
TABLE 3
Characteristics of patients according to rs13266634 genotype
R/R R/W W/W P
n (% female) 207 (35.7) 306 (37.9) 111 (27.9) 0.168*
No. of PTDM patients (%) 70 (33.8) 82 (26.8) 22 (19.8) 0.025* 0.007†
Age at transplantation (years) 39.60	 9.71 38.34	 9.06 38.16	 10.41 0.269
Family history of diabetes (%) 119 (57.5) 172 (56.2) 65 (58.6) 0.901*
Follow-up duration (months) 103.66	 62.15 101.86	 59.71 109.94	 65.03 0.495
BW at transplantation (kg) 59.09	 9.22 58.70	 10.40 58.27	 8.31 0.891
BW at 3 months after transplantation (kg) 59.01	 8.71 58.91	 9.28 58.27	 8.31 0.762
BW at 6 months after transplantation (kg) 61.28	 8.91 61.59	 9.27 60.98	 8.34 0.819

BW during first 3 months after transplantation (kg) 0.09	 4.61 0.22	 4.30 0.40	 4.63 0.430

BW during first 6 months after transplantation (kg) 2.20	 5.32 2.88	 5.43 2.31	 5.55 0.338
FPG at transplantation (mmol/l) 5.32	 1.66 5.18	 1.35 5.05	 1.06 0.316
FPG at 3 months after transplantation (mmol/l) 5.97	 2.02 5.73	 2.46 5.53	 1.00 0.334
FPG at 6 months after transplantation (mmol/l) 5.74	 1.85 5.78	 2.12 5.49	 0.87 0.527
FPG at 12 months after transplantation (mmol/l) 6.00	 2.16 5.85	 1.80 5.47	 0.73 0.060
HOMA-IR at 12 months after transplantation 3.21	 1.45 3.02	 1.62 3.94	 1.99 0.304
HOMA- at 12 months after transplantation 66.12	 45.35‡ 112.41	 60.18§ 188.32	 124.85 0.001
Duration of dialysis (months) 22.13	 31.64 16.40	 25.78 20.16	 35.90 0.079
No. of patients with acute rejection (%) 57 (27.5) 77 (25.2) 28 (25.2) 0.819*
No. of patients with tacrolimus use (%) 49 (23.7) 64 (20.9) 20 (18.0) 0.488*
Cr at 3 months after transplantation (mg/dl) 1.36	 0.43 1.33	 0.38 1.42	 0.38 0.099
Cr at 6 months after transplantation (mg/dl) 1.31	 0.38 1.31	 0.37 1.36	 0.30 0.517
Cr at 12 months after transplantation (mg/dl) 1.31	 0.50 1.30	 0.38 1.36	 0.49 0.481
Data are means	 SD or n (%). BW, body weight; 
BW, change in body weight. P values were calculated from t test. *P values were calculated
from 2 test. †P value was calculated from the Mantel-Haenzel 2 test (trend P test). ‡P  0.001 (post-hoc analysis between R/R and W/W
genotypes). §P  0.016 (post-hoc analysis between R/W and W/W genotypes).
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DISCUSSION
Zinc is thought to be an important metal for insulin storage
and secretion (16). Zinc homeostasis is regulated by the
uptake and export of zinc by specialized transporter
proteins. Insulin is stored inside secretory granules as
solid hexamers bound with two Zn2 ions per hexamer
(17,18). Zinc is likely to play a role in the stability of the
insulin hexamer and to modulate glucagon secretion in
-cells via paracrine action.
The SLC39 proteins (Zips) control the intracellular
uptake of zinc (28), and SLC30 proteins (ZnTs) control the
cellular efflux of zinc into the extracellular matrix or
intracellular vesicles (29). Among ZnTs, ZnT-8 has recently
been identified and cloned as a pancreatic -cell–specific
ZnT and is located in insulin secretory granules (19–21).
ZnT-8 is encoded by the gene SLC30A8, which is located
at chromosome 8q24.11. The polymorphism rs1326634 in
the SLC30A8 gene has been associated with type 2 diabe-
tes (22–25). In addition, recent studies have suggested that
SLC30A8 may play a role in insulin secretion in the
process of zinc incorporation into insulin vesicles (19,20).
In this study, we demonstrated the genetic influence of
the SLC30A8 polymorphism in the development of PTDM
in a renal transplant cohort. We calculated the relative
risks of the heterozygote R/W genotype and the mutant
homozygote W/W genotype compared with the wild ho-
mozygote R/R genotype because the risk allele was the
major allele (R) in a previously reported French study
(22). We found the risk of PTDM to be significantly lower
in patients who were W/W homozygotes than in patients
who were R/R wild-type homozygotes. There was also a
tendency toward a reduction in the risk of PTDM in R/W
heterozygote carriers compared with R/R carriers. We
observed a linear relationship between the number of
R-alleles and an increased incidence of PTDM. This geno-
type effect remained significant after adjustments for age,
sex, amount of body weight gain, and type of immunosup-
pressant use. These results suggest that the SLC30A8 gene
is one susceptibility gene for PTDM. Age at transplantation
and tacrolimus use as an immunosuppressant were re-
vealed as important risk factors for PTDM.
Interestingly, there was a higher mean HOMA- value in
patients carrying the W/W genotype than in those carrying
the R/R genotype. These results suggest that this polymor-
phism may be functional and have effects on insulin
secretion. There was no significant difference in HOMA-IR
value according to genotype. Numakura et al. (13) re-
ported that a vitamin D receptor (VDR) polymorphism was
associated with PTDM in 70 renal allograft recipients. The
VDR polymorphism is also reported to affect insulin secre-
tion (30–32). Their results and the results of this study are
consistent with our previous reports (10,15), in that a
defect in insulin secretion plays a more crucial role than
increased insulin resistance in the pathogenesis of PTDM.
This SLC30A8 polymorphism site is located at the
COOH-terminal region of the protein structure. The
rs1326634 SNP results in a nonsynonymous mutation
because the nucleotide change from C to T results in an
amino acid change from arginine (R) to tryptophan (W)
at position 325. This polymorphism might be a gain-of-
function mutation that increases protein expression levels,
thereby enhancing zinc transport into insulin secretory
granules. Facilitated zinc transport could influence insulin
stability and secretion. Another possibility is that the
polymorphism may affect the posttranslational modifica-
tion mechanism in the COOH terminus of ZnT-8. Until
now, information on ZnT-interacting proteins or phosphor-
ylation events in the intracellular COOH termini of all the
ZnT subfamily members has been lacking. Interestingly,
the amino acid stretch (TAASR*DSQVV) constituting R325
in the COOH terminus of ZnT-8 has a protein kinase A and
protein kinase C recognition motif (R-X-S/T). The R325W
polymorphism would disrupt this motif, which may possi-
bly prevent the receptor phosphorylation otherwise regu-
lated by serine protein kinases, leading to changes in the
transporter function. There is much that still needs to be
learned about the regulation of ZnT, and the exact molec-
ular mechanisms remain to be elucidated.
A limitation of this study is that oral glucose tolerance
tests were not routinely performed before transplantation.
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FIG. 1. Cumulative diabetes-free survival (by the Kaplan Meier
method) in the development of PTDM for patients with the R/R, R/W,
and W/W genotypes.
TABLE 4
Multivariable Cox proportional hazard regression analysis of risk factors associated with PTDM
HR (95% CI) P
Age (years) 1.05 (1.03–1.07) 0.001
Sex (0  men, 1  women) 0.93 (0.67–1.27) 0.780

BW at 6 months after transplantation 1.03 (1.00–1.06) 0.036
Immunosuppressant (0  cyclosporine A, 1  tacrolimus) 2.66 (1.85–3.82) 0.001
Genotype (0  R/R, 1  R/W) 0.77 (0.56–1.06) 0.114
Genotype (0  R/R, 1  W/W) 0.58 (0.36–0.94) 0.026

BW, change in body weight between baseline and 3 months after transplantation.
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Preexisting diabetes could lead to an overestimation in the
diagnosis of PTDM. There may also be a bias toward the
null because non-posttransplantation diabetic patients
were followed up for a shorter duration and may have
been misclassified. Another limitation is the relatively
small sample size. Thus, our study had 51% power to
detect an inverted reference odds ratio of 0.65 (1/1.53) at
  0.05 (22). Further analyses are warranted to replicate
the associations in larger populations.
In conclusion, our data suggest that the SLC30A8
rs1326634 variant is associated with a decreased risk of
PTDM and may be associated with insulin secretion. The
exact molecular mechanisms still need to be clarified.
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